All In Biotech

Free tool

FAERS Monitor: Livalo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022363 or its brand name (Livalo, Pitavastatin Calcium). Reports on generic versions are filed under their own applications.

Reports

8,612

Serious

6,027

70% of reports

Hospitalization

3,217

Death reported

706

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • myalgia480
  • diarrhoea393
  • nausea374
  • fatigue359
  • anaemia300
  • headache298
  • dizziness297
  • arthralgia295
  • rash287
  • off label use265
  • dyspnoea260
  • drug ineffective254
  • malaise253
  • pain in extremity253
  • fall246

Reports by year received

View as table
YearReports
20044
20059
200625
200738
200867
200978
2010171
2011274
2012545
2013375
2014553
2015660
2016725
2017707
2018685
2019656
2020515
2021417
2022477
2023419
2024526
2025383
2026303

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,547 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myalgiaSignal4806.96.32,434
anaemiaSignal3003.83.4634
pain in extremitySignal2532.11.9146
fall2461.81.689
arthralgia2951.71.593
rash2871.61.467
diarrhoea3931.51.464
dizziness2971.51.343
malaise2531.41.230
headache2981.21.07
nausea3741.21.08
fatigue3591.11.05
dyspnoea2601.11.03
off label use2650.70.725
drug ineffective2540.50.4161

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.